Table 1.
Baseline demographic and clinical characteristics
| Overall (N = 141) | CCTA + TEE (N = 71) | CCTA-only (N = 70) | p-value | |
|---|---|---|---|---|
| Age (mean, SD) | 61.7 (10.6) | 61.4 (8.9) | 62.2 (12.1) | .53 |
| Gender (% Male) | 96 (68.1%) | 51 (71.8%) | 45 (64.3%) | .34 |
| Race (% White) | 138 (97.9%) | 68 (95.8%) | 70 (100%) | .08 |
| Body mass index | 30.6 (6.6) | 30.7 (5.6) | 30.4 (7.6) | .82 |
| Diabetes type 2 | 14 (9.9%) | 7 (9.9%) | 7 (10.0%) | .98 |
| Hypertension | 73 (51.8%) | 44 (62.0%) | 29 (41.4%) | .02 |
| Congestive heart failure | 5 (3.5%) | 3 (4.2%) | 2 (2.9%) | .66 |
| CHADS2 VASC | .28 | |||
| 0 | 27 (19.1%) | 13 (18.3%) | 14 (20.0%) | |
| 1 | 45 (31.9%) | 27 (38.0%) | 18 (25.7%) | |
| 2–3 | 53 (37.6%) | 23 (32.4%) | 30 (42.9%) | |
| 4+ | 16 (11.3%) | 8 (11.3%) | 8 (11.4%) | |
| Beta blockers | 79 (56.0%) | 36 (50.7%) | 43 (61.4%) | .20 |
| Calcium channel blockers | 40 (28.4%) | 23 (32.4%) | 17 (24.3%) | .29 |
| ACEi/ARB | 49 (34.8%) | 27 (38.0%) | 22 (31.4%) | .41 |
| Aspirin only | 41 (29.0%) | 15 (21.1%) | 26 (37.1%) | .04 |
| Anticoagulation (Coumadin or NOAC) | 91 (64.5%) | 49 (69%.0) | 42 (60.0%) | .26 |
| No Aspirin or Anticoagulation | 9 (6.4%) | 7 (9.9%) | 2 (2.9%) | .11 |
ACEi – Angiotensin converting enzyme inhibitors; ARB – Angiotensin receptor blocker; NOAC –New oral anticoagulant.